ArticleBMC chemistry2019
Co-aminobenzamid@Al-SBA-15: a favorable catalyst in synthesis of 2,3-dihydroquinazolin-4(1
Article in BMC chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Functionalized magnetic nanoparticles with deep eutectic solvents as efficient catalyst for the green synthesis of dihydroquinazolinones.Scientific reports · 2025Article
- Synthesis of 3,4-dihydropyrimidines and octahydroquinazolinones by SBA-15 supported schiff-base iron (III) complex as durable and reusable catalyst under ultrasound irradiation.Scientific reports · 2024Article
- Sulfonated magnetic spirulina nanobiomaterial as a novel and environmentally friendly catalyst for the synthesis of dihydroquinazolin-4(1H)-ones in aqueous medium.Scientific reports · 2024Article
- FeNanoscale advances · 2023Article
- Facile synthesis of pyrazolopyridine pharmaceuticals under mild conditions using an algin-functionalized silica-based magnetic nanocatalyst (Alg@SBA-15/FeRSC advances · 2023Article
- Green preparation and characterization of AGC-ZM-2022 as a novel mesoporous silica material using palmitic acid as a natural template.RSC advances · 2023Article
- Article
- FeRSC advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel hybrid Co-aminobenzamid@Al-SBA-15 was synthesized as a modified mesoporous catalyst. To achieve this aim, the obtained materials were investigated by various techniques including Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD), N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.